N'-hydroxy-N-(3-phenylmethoxyphenyl)octanediamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'-hydroxy-N-(3-phenylmethoxyphenyl)octanediamide
• 化学式: C₂₁H₂₆N₂O₄
• 分子量: 370.4
• InChiKey: ATBABAGJVXPNMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY
  申请人：Wang Yan

  公开号：US20110091524A1

  公开（公告）日：2011-04-21

  The present invention provides, for example, methods for conveniently determining if a cancerous condition in a subject will be responsive to an IGF1R inhibitor. The invention includes patient selection methods and methods of treatment.

  本发明提供了方便确定受试者的癌症状况是否对IGF1R抑制剂具有响应的方法。该发明包括患者选择方法和治疗方法。
• FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20130243692A1

  公开（公告）日：2013-09-19

  This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan.

  本发明涉及一种评估IGF1R抑制剂（如抗IGF1R抗体）对Ewing肉瘤肿瘤治疗疗效的方法，通过确定肿瘤葡萄糖代谢水平来进行。肿瘤葡萄糖代谢可以通过艺术中已知的几种方法之一（包括FDG-PET/CT扫描）在治疗方案的早期阶段进行确定。
• IGFBP2 Biomarker
  申请人：Wang Yan

  公开号：US20150168424A1

  公开（公告）日：2015-06-18

  The present invention provides method for quickly and conveniently determining if a given treatment regimen of IGF1R inhibitor is sufficient, e.g., to saturate IGF1R receptors in the body of a subject. Several clinically relevant determinations may be made based on this point, including, for example, whether the dosage of the regimen is sufficient or should be increased.

  本发明提供了一种快速方便的方法，用于确定给定的IGF1R抑制剂治疗方案是否足够，例如，饱和受试者体内的IGF1R受体。可以基于这一点进行几个临床相关的决定，包括例如，治疗方案的剂量是否足够或应该增加。
• IGFBP2-Biomarker
  申请人：Schering Corporation

  公开号：EP2405270A1

  公开（公告）日：2012-01-11

  The present invention provides method for quickly and conveniently determining if a given treatment regimen of IGF1R inhibitor is sufficient, e.g., to saturate IGF1R receptors in the body of a subject. Several clinically relevant determinations may be made based on this point, including, for example, whether the dosage of the regimen is sufficient or should be increased.

  本发明提供了一种方法，可快速方便地确定给定的 IGF1R 抑制剂治疗方案是否足够，例如，是否能使受试者体内的 IGF1R 受体达到饱和。根据这一点可以做出若干临床相关的判断，例如包括治疗方案的剂量是否足够或是否应该增加。
• IGFBP2 BIOMARKER
  申请人：Wang Yan

  公开号：US20080112888A1

  公开（公告）日：2008-05-15

  The present invention provides method for quickly and conveniently determining if a given treatment regimen of IGF1R inhibitor is sufficient, e.g., to saturate IGF1R receptors in the body of a subject. Several clinically relevant determinations may be made based on this point, including, for example, whether the dosage of the regimen is sufficient or should be increased.